Share Name Share Symbol Market Type Share ISIN Share Description
Shire Plc LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +77.50p +2.10% 3,762.50p 3,769.00p 3,771.00p 3,783.00p 3,620.00p 3,670.00p 5,503,257 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9,229.1 393.7 34.8 116.6 34,223.03

Shire (SHP) Latest News

More Shire News
Shire Takeover Rumours

Shire (SHP) Share Charts

1 Year Shire Chart

1 Year Shire Chart

1 Month Shire Chart

1 Month Shire Chart

Intraday Shire Chart

Intraday Shire Chart

Shire (SHP) Discussions and Chat

Shire Forums and Chat

Date Time Title Posts
15/12/201719:12ADDERALL XR sales boost Shire2,019
20/7/201714:49SHIRE Pharmaceuticals832
15/2/201722:25Time to Look at Shire (SHP)-
03/12/201621:04Analysts' Perspective on Shire (SHP)-
29/8/201617:22New Opportunity for Shire (SHP)-

Add a New Thread

Shire (SHP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Shire trades in real-time

Shire (SHP) Top Chat Posts

DateSubject
16/12/2017
08:20
Shire Daily Update: Shire Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SHP. The last closing price for Shire was 3,685p.
Shire Plc has a 4 week average price of 3,513p and a 12 week average price of 3,435.50p.
The 1 year high share price is 5,067p while the 1 year low share price is currently 3,435.50p.
There are currently 909,582,311 shares in issue and the average daily traded volume is 2,473,890 shares. The market capitalisation of Shire Plc is Ā£34,223,034,451.38.
30/11/2017
17:56
justiceforthemany: But even with this plethora of problems, it is hard to see that much downside for the shares. Broker Liberum estimates that even if the entire value of Shire's hemophilia franchise were written off, a fair "risked" net present value (NPV) for the shares would be 3,419p – only 8 per cent below the current price. However, despite Roche’s success, there is still likely to be significant value in the hemophilia business as many existing users are likely to remain loyal. On Liberum's "base case" scenario, which forecasts a 25 per cent decline in non-inhibitor hemophilia sales between 2017 and 2022, the broker puts the risked NPV at 4,228p - 14 per cent above the current share price. Moreover, there are some reasons to be bullish about Shire. Its immunology division (14 per cent of annual product sales) reported 32 per cent revenue growth in the third quarter of 2017 – 18 per cent ahead of consensus forecasts – thanks to strong demand for infection prevention medicine Gammagard. Its oncology franchise is also gathering momentum, and recently launched unique products Mydayis (for attention deficit hyperactivity disorder) and Xiidra (for dry eye syndrome) are also performing well. Meanwhile, self-help offers promise. Cost savings from the integration of Baxalta led to a 3 per cent reduction in general and administration expenses to $27m in the third quarter. And a manufacturing review has identified $100m savings from 2019 with the potential to increase this to $300m by 2023. Manufacture of Cinryze should be bought in-house early next year to address the supply problems. And a strategic review of its neuroscience business could mean a spin-off to help alleviate debt issues. Bringing debt down could prove a major catalyst for the share price. Having peaked at $23.6bn after the Baxalta deal last year, net debt at the end of the third quarter was down to $20.4bn. Liberum expects year-end net debt to be less than three times cash profit at the year-end, at $19bn, a reasonably comfortable 2.2 times cash profits by the end of 2018 and net debt of a very manageable 1.5 times by 2019. This reduction in net debt could drive a serious re-rating of the shares given that, according to Bloomberg data, Shire's current forward earnings multiple of nine is in the bottom one per cent of the 10-year range.
07/11/2017
17:51
justiceforthemany: Ornskov really needs to pull his finger out and earn his salary. Ultimately the poor share price performance is his fault as he is the 'boss'. Stop the uncertainty and get the spin off plans approved and released to the market. Give a positive message re: debt and EPS moving forwards. Get a new CFO in. No large director buys for a while either. Closed period? There must be plenty interested in buying Shire at these prices.
25/10/2017
12:47
philanderer: Credit Suisse Slashes Shire Target Price, Says Discount To Peers "Unjustified" Shire's current discount to its global sector peers is unjustified, even under a worst case scenario for haemophilia and hereditary angiodema, Credit Suisse argues. In a research report published on Wednesday, the analysts said the shares were then trading at a roughly 40% discount in terms of the price-to-earnings multiple, amid suggestions that so-called 'sell-side forecasts are "unrealistic". Yet even after revisiting its own estimates for Xidra, lowering its assumptions for the HAE franchise, assuming faster erosion from competition for Lialda and lowering its haemophilia numbers, it found that the shares should be trading 23% higher. Specifically, the Swiss broker dropped its projections for the company's 2020 revenues and earnings per share by 8% and 15%, pushing their estimate of net asset value from 5590p to 5190p and the target price from 5350p to 4500p. The theoretical upside in the share price as implied by its estimates held true even under worst case scenarios for haemophilia and HAE erosion. Hence, Credit Suisse stuck by its 'outperform' recommendation on the stock. "We conclude that, despite all the recent setbacks and uncertainty, the current valuation effectively eliminates haemophilia, Xiidra & HAE income." HTTPS://uk.webfg.com/news/broker-recommendations/credit-suisse-slashes-shire-target-price-says-discount-to-peers-unjustified--2934095.html
24/10/2017
13:39
steeplejack: This share price performance,we're not far above a three low,makes the Baxalta acquisition look like an error of judgement.On Friday,the management are going to have to make a very good apologia as to why the market is an idiot and why the company is a snip at these prices.First and foremost,analysts will scour the results looking for anything that might vindicate the weakness in the share price.In that context,it's anyone's bet whether the shares slump further or enjoy a sharp recovery.I lost touch with the thinking behind this share when they broke down through £40.
17/10/2017
16:51
justiceforthemany: A dramatic slump again today then wipes out all the gains of yesterday. The only positive is the bigger shareholders are clearly getting very angry and frustrated with the share price here which may trigger some action from the board. [...] Sachem Head Capital Management reportedly wants Shire to offload or spin-off some of its assets as it grows frustrated with the falling share price
02/10/2017
10:26
steeplejack: Most private clients are understandably transfixed by the price they buy a stock at.If you'd bought Shire at say £10 the recent setback in the price would be fairly inconsequential.If however,you'd bought at £40,the recent setback might irritate,if for no other reason that you'd be running a loss and your entry point was poor.Warren Buffet is famous for saying that he'd be quite happy for the stock markets to remain closed for up to two years at a time,it'd make no difference to him,since having decided to buy a stock,he was confident in his judgement and was prepared to see it through.Not much commission for brokers if that occurred.The markets are filled with a myriad of different investors.Some are looking for income,capital gain,some become stale bulls,some are momentum traders.The trouble is that private clients have a tendency to forget why they bought a share in the first place especially if they start running losses.The fact that they are losing money clouds their judgement.The market is as much about psychology as solid data and there are operators who everyday hope to unnerve the unwary into making ill conceived snap judgements.Every now and then ,you have to determine whether you are happy to continue holding a stock immaterial of share price movements.
21/9/2017
17:51
justiceforthemany: As I said before the CEO gave a long interview with the FT a couple of months ago about how 'fed up' he was with the share price and how he felt the market was undervaluing the company. At the time the share price was 4400p. The share price is now 3800p and has been down to 3600p. Competition concerns are vague and unsubstantiated at the moment - only those 'in the know' truly know what is going on behind the scenes. Brokers continue to target as high as 6000p - they are pretty hopeless but this is a huge disparity with the current share price I guess this is what they feel Shire would be worth if someone bid. If he really is as fed up as he seems I doubt he would turn down an offer around 5000p this time. As for GBP vs USD funny how Shire gets hammered more than its peers who also have large earnings in USD.
06/9/2017
18:03
justiceforthemany: 5.09c/share so based on today's exchange rate = 3.9p/share Looking ahead and what is a fair share price here? I know brokers have been in the 6000p range which seems a way off at the moment. However based on EPS of $5/share and the current exchange rate you can see where they are getting this target from. AZN and GSK both trade on P/E's around 15. GSK is hardly a 'growth' share. Merck, Novartis & Co trade in the high 20's. Being negative lets say EPS next year falls 10% due to 'competition' and the £ strengthens (unlikely) so $1.35 = £1 Even then on a P/E of 15 the share price should be 5000p+
24/8/2017
19:00
justiceforthemany: If Shire had issued a profit warning I could understand the fall. I am sorry but when an upgrade in EPS & reduction in debt is met with a sell off and a near 20% fall in share price then yes I do become very suspicious. A forward P/E of 9 is very, very low for big pharma. I have shared my concerns with our CEO, Investor relations and the FCA. The pattern is the same also: US market opens and share price crashes here regardless of the wider index.
23/8/2017
21:16
justiceforthemany: I know it is not illegal but it sure as hell should be. No one can deny that the share price almost always automatically drops as soon as short positions are taken and any rise is squashed/suppressed. I have seen many shares where even if the wider index may be up by as much as 3% the shorted share will remain flat or even go down! Positive results, ultra-low P/E, balance sheet all go out of the window. That is inexplicable, blatant manipulation of a share price and just plain wrong. Shire is fast becoming a pretty good example of this.
Shire share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20171216 20:35:07